Lobular ectopic breast carcinoma: A case-report

Abstract

In about 1-2% of the population an incomplete regression of the embryonic mammary line occurs, which may result in the presence of ectopic breast tissue. An ectopic breast tissue carcinoma is a rare entity. The authors present a case-report of a 51-year-old female patient, with a lobular carcinoma in an axillary ectopic breast tissue submitted to surgery and adjuvant radiotherapy.

A Study on Diversity of Malignant Breast Lesions in Urban Population of Bengal – Two Year Experience in A Tertiary Care Centre

“…[18][19][20] Because of the rarity of these tumors, there is no consensus regarding optimal treatment and it is difficult to conduct large studies to define the optimal adjuvant treatment. Most cases have been treated with standard therapy as there are no data to indicate special protocols.…”

Rare breast tumors: Review of the literature

“…Phyllodes tumors exist in benign (35-64%), borderline, and malignant subtypes, although there is no uniform agreement on the criteria for assigning a subtype or for predicting biological behavior. 4 A subtype of phyllodes tumors appears to be less important for the risk of recurrence than does the margin of tumor-free resection achieved by surgical treatment. Phyllodes tumors are usually benign, but recurrences are not uncommon, and a relatively small number of patients will develop hamatogenous metastases.…”

“…Phyllodes tumors often appear on ultrasound and mammography as fibroadenomas, and core needle biopsy seems inadequate to reliably distinguish phyllodes tumor from fibroadenoma. 4 Local recurrences of phyllodes tumors are the most common site of recurrence. Positive margins, fibroproliferation in the surrounding breast tissue, and necrosis are associated with a marked increase in local recurrence rates.…”

“…However, breast tumors exhibit a wide range of morphological phenotypes and rare specific histopathological types (less of 2% of all breast cancer) have particular prognostic or clinical characteristics. [2][3][4] Because of the rarity of these tumors, there is no consensus regarding optimal treatment and it is difficult to allow large studies to define the optimal adjuvant treatment. Most cases have been treated with standard therapy as there are no data to indicate special protocols.…”

“…6 However, the incidence of axillary metastases may range from 4% to 17%. 4,8 Thus, the use of sentinel lymph node biopsy (SLNB) should be considered for patients with tubular carcinoma if the positive biopsy finding will modify adjuvant treatment. 2 However, the survival of patients with tubular carcinoma is similar to that of the general population, and there is no evidence that adjuvant therapy due to positive SLNB influences survival.…”